Ro15-4513

Ro15-4513
Systematic (IUPAC) name
Ethyl-8-azido-5,6-dihydro-5-methyl-6-oxo-4H-imidazo-1,4-benzodiazepine-3-carboxylate
Identifiers
CAS Number 91917-65-6 N
PubChem CID 5081
IUPHAR/BPS 4296
ChemSpider 4903 YesY
ChEMBL CHEMBL6597 YesY
Chemical data
Formula C15H14N6O3
Molar mass 326.31 g/mol
 NYesY (what is this?)  (verify)

Ro15-4513 is a weak partial inverse agonist of the benzodiazepine class of drugs, developed by Hoffmann–La Roche in the 1980s.[1] It acts as a competitive antagonist, and can therefore be an antidote to the acute impairment caused by alcohol.

Ro15-4513 is structurally related to the benzodiazepine antidote flumazenil.

Uses

Original development as alcohol antidote

The main interest in Ro15-4513 was as an antidote to alcohol. Flumazenil effectively blocks the effects of benzodiazepine agonists such as alprazolam and diazepam and so is used for treating overdoses of these drugs but is ineffective in blocking alcohol actions. Ro15-4513 was somewhat less effective than flumazenil at blocking the effects of benzodiazepines, but instead selectively blocked the effects of ethanol. This meant that in contrast to flumazenil, which is ineffective at treating alcohol overdoses, Ro15-4513 showed potential as a useful alcohol antidote. It is thought that Ro15-4513 antagonizes the effects of ethanol because the azido group at the 8- position of the benzene ring blocks the binding site for ethanol on the α4β3δ subtype of the GABAA receptor; flumazenil, which has a fluorine at this position, does not block this binding site and so does not counteract the effects of ethanol.

Unfortunately Ro15-4513 had several disadvantages that made it unsuitable for development and marketing. Its fairly short half-life means that several repeated doses would have to be given over an extended period, since if only one dose were used it would wear off before the alcohol had been metabolised and the patient would relapse (similar to the problems with renarcotization seen when treating overdoses of long-acting opioids such as methadone with short-acting antagonists such as naloxone). Also because of its GABA antagonist effects, Ro15-4513 causes serious side-effects including both anxiety, and at higher doses, convulsions, which would require careful control of dosing and would cause complications in clinical use. Another problem is that alcohol's effects are not purely mediated by GABA receptors; at higher doses alcohol binds to several other targets as well, so while Ro15-4513 is an effective antidote against moderate levels of alcohol intoxication, it might be ineffective at treating life-threatening overdoses.

Also, Roche was concerned about the legal implications of introducing an alcohol antidote, as Ro15-4513 blocks the effects of ethanol but does not remove it from the bloodstream, which could lead to potential problems, as the effects of the alcohol would be masked only temporarily. As a result, patients might, for instance, feel that they are sober and discharge themselves from hospital once the drug took effect, then become drunk again once it wore off, possibly crashing their car or having other accidents that might lead to legal consequences for Roche.

However, the discovery of Ro15-4513 has been important in elucidating the mechanism of action of ethanol as used as a recreational drug, and this compound could now be used as a template to design a more effective and longer-lasting antidote for ethanol, or alternatively to develop a selective agonist drug that could replicate the desired effects of alcohol, but with fewer side effects.

Current use in PET Imaging

Labelling Ro15-4513 with carbon-11 leads to the possibility of its use in PET imaging of the brain. The specificity of the compound to a small number of GABA receptor sub-types leads to the generation, with accurate modelling, of detailed images with well-defined limbic and cortical structures. These images can be useful in quantitatively analysing conditions such as addiction, that are known to be, at least in part, associated with the GABAergic system. The images produced are similar to those for labelled flumazenil, though the distribution varies especially in regions such as the occipital lobe, cerebellum, and basal ganglia, as it does not selectively label the GABRA1 subtype.[2][3][4][5][6]

See also

References

  1. ↑ US patent 4868176, Gardner CR, Hedgecook JR, "Novel imidazobenzodiazepines", issued 1989-09-19, assigned to Roussel Uclaf
  2. ↑ Sieghart W (1994). "Pharmacology of benzodiazepine receptors: an update". J Psychiatry Neurosci 19 (1): 24–9. PMC 1188559. PMID 8148363.
  3. ↑ Mehta AK, Ticku MK (1988). "Ethanol potentiation of GABAergic transmission in cultured spinal cord neurons involves gamma-aminobutyric acidA-gated chloride channels". J. Pharmacol. Exp. Ther. 246 (2): 558–64. PMID 2457076.
  4. ↑ Becker HC, Anton RF (1989). "The benzodiazepine receptor inverse agonist RO15-4513 exacerbates, but does not precipitate, ethanol withdrawal in mice". Pharmacol. Biochem. Behav. 32 (1): 163–7. doi:10.1016/0091-3057(89)90227-X. PMID 2543989.
  5. ↑ Wallner M, Hanchar HJ, Olsen RW (2006). "Low-dose alcohol actions on α4β3δ GABAA receptors are reversed by the behavioral alcohol antagonist Ro15-4513". Proc. Natl. Acad. Sci. U.S.A. 103 (22): 8540–5. doi:10.1073/pnas.0600194103. PMC 1482527. PMID 16698930.
  6. ↑ Hanchar HJ, Chutsrinopkun P, Meera P, Supavilai P, Sieghart W, Wallner M, Olsen RW (2006). "Ethanol potently and competitively inhibits binding of the alcohol antagonist Ro15-4513 to α4/6β3δ GABAA receptors". Proc. Natl. Acad. Sci. U.S.A. 103 (22): 8546–51. doi:10.1073/pnas.0509903103. PMC 1482528. PMID 16581914.
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.